The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies
Treatments for multiple myeloma (MM) in newly diagnosed and relapsed patients differ between regions, particularly with the rapid advancements in treatment in recent years. Here, Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, discusses how MM is treated in the US; highlighting the differences compared with Europe, as a European who now works in the US. Notably, the use of more drugs in combination; namely IMiDs, proteasome inhibitors and steroids, although four-agent regimens with the addition of a monoclonal antibody are in clinical trials. Dr Landgren also discusses the future of MM treatment in the US, with research investigating CAR T-cells, bispecific antibodies and antibody-drug conjugates. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
